Business Standard

Sun Pharma Q4 net at Rs 820 cr

Appoints Israel Makov as the chairman in place of Dilip Shanghvi

Related News

Sun Pharmaceutical Industries Ltd today reported a consolidated of Rs 820.21 crore for the fourth quarter ended March 31, 2012.

The company had posted a net profit of Rs 442.75 crore for the same period of previous fiscal, said in a filing to the BSE.

of the company stood at Rs 2,329.93 for the fourth quarter ended March 31, 2012 as against Rs 1,463.28 crore during the corresponding period of previous fiscal.

For the year ended March 31, 2012, the company posted a net profit of Rs 2,587.25 crore compared to Rs 1,816.06 crore in 2010-11.

"Taro Pharmaceutical Industries became a subsidiary of the company on September 20, 2010 therefore the figures for the current fiscal are not comparable with the corresponding figures for the previous financial year," the company said.

The company's board, which met today, recommended a dividend of Rs 4.25 per equity share of Re 1 each for the financial year ended March 31, 2012.

In a separate filing the company said it has appointed as the Chairman of the company in place of Dilip Shanghvi, who has has stepped down from the position while continuing to remain as the company's Managing Director.

The company's board has also appointed Makov, a resident of Israel, as an additional director on the company's board, it said.

Shares of Sun Pharma today closed at Rs 565.65 on the BSE, down 0.68% from its previous close.

Read more on:   
|
|
|
|

Sun Pharma Q4 net at Rs 820 cr

Appoints Israel Makov as the chairman in place of Dilip Shanghvi

The company had posted a net profit of Rs 442.75 crore for the same period of previous fiscal, Sun Pharma said in a filing to the BSE.

Sun Pharmaceutical Industries Ltd today reported a consolidated of Rs 820.21 crore for the fourth quarter ended March 31, 2012.

The company had posted a net profit of Rs 442.75 crore for the same period of previous fiscal, said in a filing to the BSE.

of the company stood at Rs 2,329.93 for the fourth quarter ended March 31, 2012 as against Rs 1,463.28 crore during the corresponding period of previous fiscal.

For the year ended March 31, 2012, the company posted a net profit of Rs 2,587.25 crore compared to Rs 1,816.06 crore in 2010-11.

"Taro Pharmaceutical Industries became a subsidiary of the company on September 20, 2010 therefore the figures for the current fiscal are not comparable with the corresponding figures for the previous financial year," the company said.

The company's board, which met today, recommended a dividend of Rs 4.25 per equity share of Re 1 each for the financial year ended March 31, 2012.

In a separate filing the company said it has appointed as the Chairman of the company in place of Dilip Shanghvi, who has has stepped down from the position while continuing to remain as the company's Managing Director.

The company's board has also appointed Makov, a resident of Israel, as an additional director on the company's board, it said.

Shares of Sun Pharma today closed at Rs 565.65 on the BSE, down 0.68% from its previous close.

image

Read More

Lupin Q3 net up 43% at Rs 335 cr

Consolidated net sales of the company rose by 38% to Rs 2,465.9 cr

Recommended for you

Quick Links

Results Calendar
Rss icon May 2015 Rss icon
Sun Mon Tue Wed Thu Fri Sat
12
3456789
10111213141516
17181920212223
24252627282930
31
Results Tracker
Available for 279 companies
Quarter Mar 2015 Mar 2014 % chg
Sales 385,065.84 403,617.91 -4.60
Op. Profit 115,758.30 130,168.89 -11.07
Net Profit 27,280.31 50,118.34 -45.57
Figures in Rs crore

Back to Top